One significant step forward in the fight against Malaria
15 SEP 2017
First Subject Dosed in M5717 Phase I Trial
The M5717 PeEF2 inhibitor team has achieved a major milestone!
The first subject in the Phase I trial was dosed on September 14, 2017.
M5717 has the potential to become the first single-dose treatment for cure and prophylaxis of malaria.
Performed in Australia with healthy volunteers, the Phase I trial aims to assess the safety and obtain an early read-out of the antimalarial activity of M5717 in human to confirm the potential for single dose cure.